S
ST Pharm Co Ltd
KOSDAQ:237690
ST Pharm Co Ltd
KOSDAQ:237690
Price:
86 100
KRW
0.94%
Market Closed
Market Cap:
1.7T
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
ST Pharm Co Ltd
86100
+800 (+0.94%)
| 52 Week Range |
60 400
117 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
ST Pharm Co Ltd
Balance Sheet
Balance Sheet Decomposition
ST Pharm Co Ltd
ST Pharm Co Ltd
| Current Assets | 348.4B |
| Cash & Short-Term Investments | 90.1B |
| Receivables | 122.6B |
| Other Current Assets | 135.7B |
| Non-Current Assets | 327.1B |
| Long-Term Investments | 17.7B |
| PP&E | 280.1B |
| Intangibles | 13.5B |
| Other Non-Current Assets | 15.7B |
| Current Liabilities | 83.7B |
| Accounts Payable | 17.7B |
| Accrued Liabilities | 8.3B |
| Short-Term Debt | 20.9B |
| Other Current Liabilities | 36.9B |
| Non-Current Liabilities | 207.1B |
| Long-Term Debt | 161.8B |
| Other Non-Current Liabilities | 45.3B |
Balance Sheet
ST Pharm Co Ltd
ST Pharm Co Ltd
Currency: KRW
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
2 443
|
11 804
|
55 196
|
72 301
|
47 709
|
12 823
|
38 625
|
39 203
|
50 201
|
50 097
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
12 748
|
29 921
|
27 348
|
50 201
|
50 097
|
|
| Cash Equivalents |
2 443
|
11 804
|
55 196
|
72 301
|
47 709
|
75
|
8 704
|
11 855
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
60 000
|
60 000
|
60 000
|
52 216
|
102 011
|
54 013
|
0
|
40 000
|
|
| Total Receivables |
19 212
|
16 636
|
17 968
|
30 279
|
17 298
|
35 951
|
46 762
|
64 448
|
97 871
|
122 627
|
|
| Accounts Receivables |
15 239
|
13 234
|
13 671
|
30 155
|
15 737
|
35 572
|
45 515
|
63 248
|
94 350
|
121 290
|
|
| Other Receivables |
3 973
|
3 402
|
4 297
|
124
|
1 561
|
379
|
1 247
|
1 200
|
3 522
|
1 336
|
|
| Inventory |
34 961
|
58 710
|
91 371
|
57 975
|
40 659
|
40 925
|
45 401
|
80 809
|
107 623
|
120 736
|
|
| Other Current Assets |
155
|
8 629
|
340
|
4 650
|
1 632
|
2 237
|
2 813
|
5 668
|
7 539
|
14 918
|
|
| Total Current Assets |
56 771
|
95 779
|
224 875
|
225 205
|
167 299
|
144 152
|
235 613
|
244 142
|
263 234
|
348 378
|
|
| PP&E Net |
63 759
|
134 099
|
138 430
|
151 580
|
169 069
|
170 980
|
175 634
|
210 190
|
257 885
|
280 105
|
|
| PP&E Gross |
63 759
|
134 099
|
138 430
|
151 580
|
169 069
|
170 980
|
175 634
|
210 190
|
257 885
|
280 105
|
|
| Accumulated Depreciation |
42 175
|
47 284
|
55 900
|
60 453
|
68 630
|
96 349
|
109 232
|
116 462
|
126 187
|
146 440
|
|
| Intangible Assets |
829
|
1 092
|
1 080
|
1 211
|
1 407
|
1 310
|
1 952
|
4 164
|
3 532
|
3 513
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
7 791
|
8 044
|
8 455
|
8 947
|
9 950
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
16 185
|
0
|
1 037
|
471
|
1 059
|
3 006
|
7 756
|
13 264
|
11 492
|
17 749
|
|
| Other Long-Term Assets |
4 829
|
1 397
|
2 357
|
3 037
|
6 671
|
13 370
|
16 572
|
18 351
|
25 563
|
15 741
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
7 791
|
8 044
|
8 455
|
8 947
|
9 950
|
|
| Total Assets |
142 373
N/A
|
232 367
+63%
|
367 779
+58%
|
381 504
+4%
|
345 505
-9%
|
340 610
-1%
|
445 570
+31%
|
498 565
+12%
|
570 652
+14%
|
675 436
+18%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
4 200
|
10 862
|
13 689
|
3 111
|
3 086
|
7 164
|
4 694
|
12 865
|
18 095
|
17 661
|
|
| Accrued Liabilities |
3 840
|
4 507
|
4 700
|
3 078
|
2 503
|
2 611
|
3 097
|
6 558
|
9 365
|
8 264
|
|
| Short-Term Debt |
32 500
|
32 500
|
0
|
0
|
0
|
0
|
0
|
0
|
20 000
|
20 878
|
|
| Current Portion of Long-Term Debt |
38 668
|
16 475
|
1 383
|
20
|
20
|
443
|
894
|
15 587
|
95 333
|
9 372
|
|
| Other Current Liabilities |
3 240
|
43 884
|
31 702
|
22 430
|
4 345
|
6 009
|
9 925
|
40 355
|
36 431
|
27 570
|
|
| Total Current Liabilities |
82 447
|
108 227
|
51 473
|
28 638
|
9 954
|
16 227
|
18 610
|
75 365
|
179 224
|
83 745
|
|
| Long-Term Debt |
176
|
10 156
|
137
|
117
|
98
|
15 551
|
126 033
|
91 930
|
19 188
|
161 832
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
2 387
|
1 425
|
3 058
|
3 471
|
2 356
|
|
| Other Liabilities |
2 571
|
3 110
|
2 924
|
1 667
|
3 885
|
5 622
|
4 174
|
5 237
|
31 138
|
42 953
|
|
| Total Liabilities |
85 193
N/A
|
121 493
+43%
|
54 534
-55%
|
30 421
-44%
|
13 936
-54%
|
39 788
+186%
|
150 242
+278%
|
175 591
+17%
|
233 020
+33%
|
290 886
+25%
|
|
| Equity | |||||||||||
| Common Stock |
4 191
|
5 891
|
9 242
|
9 328
|
9 328
|
9 328
|
9 328
|
9 404
|
9 404
|
9 404
|
|
| Retained Earnings |
51 516
|
76 036
|
133 994
|
170 591
|
151 644
|
123 561
|
111 634
|
115 590
|
126 893
|
135 729
|
|
| Additional Paid In Capital |
2 635
|
26 222
|
170 032
|
171 287
|
171 287
|
168 725
|
174 919
|
195 714
|
195 747
|
225 940
|
|
| Unrealized Security Profit/Loss |
1 162
|
0
|
69
|
0
|
631
|
823
|
897
|
1 011
|
1 870
|
1 036
|
|
| Other Equity |
0
|
2 725
|
45
|
123
|
58
|
31
|
344
|
3 276
|
7 457
|
14 513
|
|
| Total Equity |
57 180
N/A
|
110 874
+94%
|
313 245
+183%
|
351 083
+12%
|
331 569
-6%
|
300 822
-9%
|
295 328
-2%
|
322 974
+9%
|
337 632
+5%
|
384 550
+14%
|
|
| Total Liabilities & Equity |
142 373
N/A
|
232 367
+63%
|
367 779
+58%
|
381 504
+4%
|
345 505
-9%
|
340 610
-1%
|
445 570
+31%
|
498 565
+12%
|
570 652
+14%
|
675 436
+18%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
8
|
12
|
18
|
19
|
19
|
19
|
19
|
19
|
19
|
19
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
